Evidence for orexinergic mechanisms in migraine

Neurobiology of Disease

Volumn 74, Issue , 2015, Pages 137-143

  Hoffmann, Jan ^a,d   Supronsinchai, Weera ^a,e   Akerman, Simon ^a   Andreou, Anna P ^a,f   Winrow, Christopher J ^c   Renger, John ^c   Hargreaves, Richard ^c   Goadsby, Peter J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c MERCK RESEARCH LABORATORIES   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e CHULALONGKORN UNIVERSITY   (Thailand)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Dual orexin receptor antagonists; Headache; Migraine; Orexin; Sleep

Indexed keywords

SUVOREXANT; AZEPINE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; CENTRAL NERVOUS SYSTEM AGENTS; DUAL OREXIN RECEPTOR ANTAGONIST 12; OREXIN RECEPTOR; OREXIN RECEPTOR ANTAGONIST; POTASSIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DRUG MECHANISM; DRUG STRUCTURE; ELECTROSTIMULATION; IN VIVO STUDY; MALE; MENINGEAL ARTERY; MIGRAINE AURA; NERVE CELL; NEUROPROTECTION; NOCICEPTION; NONHUMAN; PHARMACOLOGICAL BLOCKING; RAT; SPREADING CORTICAL DEPRESSION; TRIGEMINAL NERVE; TRIGEMINOCERVICAL NEURON; TRIGEMINOVASCULAR NOCICEPTION; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MICROELECTRODE; MIGRAINE DISORDERS; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; VASODILATATION;

ANIMALS; AZEPINES; BENZIMIDAZOLES; CENTRAL NERVOUS SYSTEM AGENTS; CORTICAL SPREADING DEPRESSION; DISEASE MODELS, ANIMAL; ELECTRIC STIMULATION; MALE; MICROELECTRODES; MIGRAINE DISORDERS; NOCICEPTION; OREXIN RECEPTOR ANTAGONISTS; OREXIN RECEPTORS; POTASSIUM CHLORIDE; RATS, SPRAGUE-DAWLEY; TRIGEMINAL NERVE; VASODILATION;

EID: 84949115317     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.10.022     Document Type: Article

References (58)

1. Akerman S., Goadsby P.J. Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura. NeuroReport 2005, 16:1383-1387.
2. Akerman S., et al. Diencephalic and brainstem mechanisms in migraine. Nat. Rev. Neurosci. 2011, 12:570-584.
3. Akerman S., et al. Endocannabinoids in the brainstem modulate dural trigeminovascular nociceptive traffic via CB1 and 'triptan' receptors: implications in migraine. J. Neurosci. 2013, 33:14869-14877.
4. Alstadhaug K., et al. Insomnia and circadian variation of attacks in episodic migraine. Headache 2007, 47:1181-1188.
5. Bartsch T., et al. Differential modulation of nociceptive dural input to [hypocretin] Orexin A and B receptor activation in the posterior hypothalamic area. Pain 2004, 109:367-378.
6. Benjamin L., et al. Hypothalamic activation after stimulation of the superior sagittal sinus in the cat: a Fos study. Neurobiol. Dis. 2004, 16:500-505.
7. Bergerot A., et al. Animal models of migraine. Looking at the component parts of a complex disorder. Eur. J. Neurosci. 2006, 24:1517-1534.
8. Boutrel B., et al. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:19168-19173.
9. Charbit A.R., et al. Neurons of the dopaminergic/CGRP A11 cell group modulate neuronal firing in the trigeminocervical complex: an electrophysiological and immunohistochemical study. J. Neurosci. 2009, 29:12532-12541.
10. Chemelli R.M., et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999, 98:437-451.
11. Coleman P.J., et al. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. ChemMedChem 2012, 7(415-24):337.
12. Cox C.D., et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J. Med. Chem. 2010, 53:5320-5332.
13. Dahmen N., et al. Increased frequency of migraine in narcoleptic patients. Neurology 1999, 52:1291-1293.
14. Date Y., et al. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:748-753.
15. de Lecea L., et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:322-327.
16. Denuelle M., et al. Hypothalamic activation in spontaneous migraine attacks. Headache 2007, 47:1418-1426.
17. Denuelle M., et al. Posterior cerebral hypoperfusion in migraine without aura. Cephalalgia 2008, 28:856-862.
18. Ferguson A.V., Samson W.K. The orexin/hypocretin system: a critical regulator of neuroendocrine and autonomic function. Front. Neuroendocrinol. 2003, 24:141-150.
19. Field A. Discovering Statistics Using SPSS for Windows 2000, SAGE Publications, London.
20. George C.F., Singh S.M. Hypocretin (orexin) pathway to sleep. Lancet 2000, 355:6.
21. Giffin N.J., et al. Premonitory symptoms in migraine: an electronic diary study. Neurology 2003, 60:935-940.
22. Goadsby P.J. Pathophysiology of migraine. Neurol. Clin. North Am. 2009, 27:335-360.
23. Goadsby P.J., Sprenger T. Current practice and future directions in the management of migraine: acute and preventive. Lancet Neurol. 2010, 9:285-298.
24. Goadsby P.J., et al. Migraine - current understanding and treatment. N. Engl. J. Med. 2002, 346:257-270.
25. Gotter A.L., et al. Orexin receptors as therapeutic drug targets. Prog. Brain Res. 2012, 198:163-188.
26. Gotter A.L., et al. International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology. Pharmacol. Rev. 2012, 64:389-420.
27. Hagan J.J., et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:10911-10916.
28. Herring W.J., et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology 2012, 79:2265-2274.
29. Hoffmann J., et al. Dual Orexin receptor antagonists inhibit nociceptive neuronal activity in the trigeminocervical complex of the rat. Neurology 2013, S55:006.
30. Holland P.R., Goadsby P.J. The hypothalamic orexinergic system: pain and primary headaches. Headache 2007, 47:951-962.
31. Holland P.R., et al. Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception. J. Pharmacol. Exp. Ther. 2005, 315:1380-1385.
32. Holland P.R., et al. Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur. J. Neurosci. 2006, 24:2825-2833.
33. 1B/1D receptor antagonism. Ann. Neurol. 2008, 64:S26.
34. Holland P.R., et al. Acid-sensing ion channel-1: a novel therapeutic target for migraine with aura. Ann. Neurol. 2012, 72:559-563.
35. Lee M.G., et al. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J. Neurosci. 2005, 25:6716-6720.
36. Lipton R.B., et al. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001, 41:638-645.
37. Maniyar F.H., et al. Brain activations in the premonitory phase of nitroglycerin triggered migraine attacks. Brain 2014, 137:232-242.
38. Marcus J.N., et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J. Comp. Neurol. 2001, 435:6-25.
39. Murray C.J., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2197-2223.
40. Nambu T., et al. Distribution of orexin neurons in the adult rat brain. Brain Res. 1999, 827:243-260.
41. Ozcan M., et al. Orexins activates protein kinase C-mediated Ca(2+) signaling in isolated rat primary sensory neurons. Physiol. Res. 2010, 59:255-262.
42. Peyron C., et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 1998, 18:9996-10015.
43. Peyron C., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 2000, 6:991-997.
44. Rasmussen B.K. Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain 1993, 53:65-72.
45. Robert C., et al. Paraventricular hypothalamic regulation of trigeminovascular mechanisms involved in headaches. J. Neurosci. 2013, 33:8827-8840.
46. Sakurai T. Reverse pharmacology of orexin: from an orphan GPCR to integrative physiology. Regul. Pept. 2005, 126:3-10.
47. Sakurai T., et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92:696-697.
48. Samson W.K., et al. Non-sleep effects of hypocretin/orexin. Sleep Med. Rev. 2005, 9:243-252.
49. Sarchielli P., et al. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: findings from cerebrospinal fluid. Cephalalgia 2008, 28:714-722.
50. Scammell T.E., Winrow C.J. Orexin receptors: pharmacology and therapeutic opportunities. Annu. Rev. Pharmacol. Toxicol. 2011, 51:243-266.
51. Siegel J.M. Narcolepsy: a key role for hypocretins (orexins). Cell 1999, 98:409-412.
52. Siegel J.M. Hypocretin (orexin): role in normal behavior and neuropathology. Annu. Rev. Psychol. 2004, 55:125-148.
53. Smart D., Jerman J. The physiology and pharmacology of the orexins. Pharmacol. Ther. 2002, 94:51.
54. Supornsilpchai W., et al. Cortical hyperexcitability and mechanism of medication-overuse headache. Cephalalgia 2010, 30:1101-1109.
55. Supronsinchai W., et al. The role of the orexin-2 receptor in the nucleus raphe magnus on trigeminovascular nociceptive transmission. Cephalalgia 2013, 33:223.
56. van den Pol A.N. Hypothalamic hypocretin (orexin): robust innervation of the spinal cord. J. Neurosci. 1999, 19:3171-3182.
57. Williamson D.J., et al. Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural blood vessel diameter in the anaesthetized rat. Cephalalgia 1997, 17:518-524.
58. Wober C., et al. Prospective analysis of factors related to migraine attacks: the PAMINA study. Cephalalgia 2007, 27:304-314.